7.16
-0.03
(-0.49%)
As of 8:28:32 AM GMT+1. Market Open.
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Cash Flows from Used in Operating Activities Direct
37,053.88
37,053.88
36,912.06
39,872.28
19,262.06
Investing Cash Flow
-29,033.93
-29,033.93
-1,027.53
-434.44
-854.33
Financing Cash Flow
-3,571.81
-3,571.81
-2,240.13
-1,503.76
-1,479.95
End Cash Position
35,200.75
35,200.75
156,813.54
121,509.28
82,690.98
Income Tax Paid Supplemental Data
15,648.11
15,648.11
7,744.92
--
--
Capital Expenditure
-5,576.22
-5,576.22
-1,027.53
-434.44
-854.33
Issuance of Capital Stock
4,155.01
4,155.01
--
--
--
Repurchase of Capital Stock
-4,909.25
-4,909.25
--
--
--
Free Cash Flow
31,477.67
31,477.67
35,884.53
39,437.84
18,407.74
6/30/2021 - 8/16/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PVLA Palvella Therapeutics, Inc.
13.50
+1.43%
GLTO Galecto, Inc.
4.9300
-2.76%
BOLT Bolt Biotherapeutics, Inc.
0.5029
+0.90%
IPSC Century Therapeutics, Inc.
0.8500
+3.13%
PHM.MC Pharma Mar, S.A.
88.10
+3.77%
PULM Pulmatrix, Inc.
7.67
-1.79%
CGEM Cullinan Therapeutics, Inc.
10.98
-2.40%
REPL Replimune Group, Inc.
13.62
-3.20%
IKT Inhibikase Therapeutics, Inc.
1.9200
-31.43%
URGN UroGen Pharma Ltd.
11.35
+3.09%